Pfizer Geodon CV Safety Trial Fully Enrolled; Rx Growth Slows
Executive Summary
Pfizer has completed enrollment in a cardiovascular safety study of the antipsychotic Geodon (ziprasidone), the company told investors during an Oct. 17 conference call.
You may also be interested in...
Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk
Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)
Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk
Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients